SG Americas Securities LLC grew its stake in Esperion Therapeutics Inc (NASDAQ:ESPR) by 236.9% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 14,840 shares of the biopharmaceutical company’s stock after buying an additional 10,435 shares during the period. SG Americas Securities LLC’s holdings in Esperion Therapeutics were worth $596,000 at the end of the most recent reporting period.

Several other institutional investors also recently modified their holdings of ESPR. Hsbc Holdings PLC acquired a new position in shares of Esperion Therapeutics in the 4th quarter valued at $11,067,000. FMR LLC raised its position in Esperion Therapeutics by 43.8% in the 4th quarter. FMR LLC now owns 739,289 shares of the biopharmaceutical company’s stock valued at $34,007,000 after purchasing an additional 225,205 shares during the last quarter. Rhenman & Partners Asset Management AB raised its position in Esperion Therapeutics by 35.5% in the 1st quarter. Rhenman & Partners Asset Management AB now owns 479,767 shares of the biopharmaceutical company’s stock valued at $19,263,000 after purchasing an additional 125,806 shares during the last quarter. Norges Bank purchased a new stake in Esperion Therapeutics in the 4th quarter valued at $5,536,000. Finally, BB Biotech AG raised its position in Esperion Therapeutics by 3.4% in the 4th quarter. BB Biotech AG now owns 3,392,964 shares of the biopharmaceutical company’s stock valued at $156,076,000 after purchasing an additional 110,000 shares during the last quarter.

Shares of Esperion Therapeutics stock opened at $51.57 on Wednesday. The firm has a market cap of $1.39 billion, a price-to-earnings ratio of -6.84 and a beta of 2.11. Esperion Therapeutics Inc has a one year low of $35.80 and a one year high of $60.99.

Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings data on Wednesday, May 8th. The biopharmaceutical company reported $3.07 EPS for the quarter, topping the Zacks’ consensus estimate of $0.64 by $2.43. The firm had revenue of $145.42 million for the quarter, compared to analysts’ expectations of $69.35 million. During the same quarter in the previous year, the company posted ($1.73) EPS. As a group, sell-side analysts expect that Esperion Therapeutics Inc will post -2.09 earnings per share for the current year.

Several research firms recently commented on ESPR. ValuEngine upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a research report on Friday, May 3rd. Stifel Nicolaus reiterated a “buy” rating and issued a $112.00 price target on shares of Esperion Therapeutics in a research report on Friday, March 29th. Credit Suisse Group upped their price target on shares of Esperion Therapeutics from $79.00 to $90.00 and gave the company an “outperform” rating in a research report on Monday, May 6th. BidaskClub upgraded shares of Esperion Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, January 31st. Finally, Zacks Investment Research downgraded shares of Esperion Therapeutics from a “hold” rating to a “sell” rating in a research report on Friday, February 8th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus target price of $75.45.

In other news, Director Roger S. Newton sold 25,000 shares of the stock in a transaction dated Tuesday, March 12th. The shares were sold at an average price of $50.06, for a total value of $1,251,500.00. Following the completion of the transaction, the director now owns 548,726 shares in the company, valued at approximately $27,469,223.56. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Timothy M. Mayleben purchased 5,000 shares of the business’s stock in a transaction dated Thursday, March 14th. The stock was bought at an average price of $48.73 per share, with a total value of $243,650.00. Following the acquisition, the chief executive officer now directly owns 51,163 shares in the company, valued at $2,493,172.99. The disclosure for this purchase can be found here. In the last 90 days, insiders have acquired 65,000 shares of company stock valued at $3,155,550 and have sold 48,329 shares valued at $2,280,206. 7.70% of the stock is currently owned by corporate insiders.

COPYRIGHT VIOLATION WARNING: This news story was originally published by Watch List News and is owned by of Watch List News. If you are viewing this news story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this news story can be viewed at https://www.watchlistnews.com/esperion-therapeutics-inc-espr-shares-bought-by-sg-americas-securities-llc/3018591.html.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a lipid management company, focuses on developing and commercializing oral therapies for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its lead product candidate is bempedoic acid/ezetimibe combination pill, a non-statin, orally available, LDL-C lowering therapy for patients with hypercholesterolemia and with atherosclerotic cardiovascular disease, and/or heterozygous familial hypercholesterolemia that is in Phase III long-term safety and tolerability study.

Further Reading: How Do Front-End Loads Impact an Investment?

Want to see what other hedge funds are holding ESPR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Esperion Therapeutics Inc (NASDAQ:ESPR).

Institutional Ownership by Quarter for Esperion Therapeutics (NASDAQ:ESPR)

Receive News & Ratings for Esperion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.